10-Q: Zeo ScientifiX Reports Strong Revenue Growth in Q2 2026

Zeo ScientifiX, Inc. announced a significant increase in revenue for the second quarter of fiscal year 2026, driven by strong performance in its allogenic biologic products.

Summary

• Zeo ScientifiX, Inc. reported revenues of $2.581 million for the three months ended April 30, 2026, a substantial increase of 124.6% compared to $1.149 million in the same period last year.
• For the six months ended April 30, 2026, revenues reached $4.027 million, up 79.9% from $2.239 million in the prior year period.
• The company experienced a net loss of $145,000 for the three months ended April 30, 2026, an improvement from a net loss of $1.391 million in the prior year period.
• For the six months ended April 30, 2026, the net loss was $997,000, compared to $2.634 million for the same period in 2025.
• Cash reserves increased significantly, with cash at the end of the period at $1.846 million, up from $542,000 at the end of the prior year period.
• The company is facing substantial doubt about its ability to continue as a going concern, despite the revenue growth.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with strong revenue growth and improved net loss figures, but significant ongoing concerns regarding going concern status and regulatory uncertainties.

Positives

• Revenue for the three months ended April 30, 2026, increased by 124.6% to $2.581 million, compared to $1.149 million in the prior year period.
• Revenue for the six months ended April 30, 2026, increased by 79.9% to $4.027 million, compared to $2.239 million in the prior year period.
• Gross profit for the three months ended April 30, 2026, was $2.055 million (79.6% of revenues), an increase of 130.1% from the prior year period.
• Gross profit for the six months ended April 30, 2026, was $3.220 million (80.0% of revenues), an increase of 79.7% from the prior year period.
• Net loss for the three months ended April 30, 2026, improved to $145,000 from $1.391 million in the prior year period.
• Net loss for the six months ended April 30, 2026, improved to $997,000 from $2.634 million in the prior year period.
• Cash and cash equivalents increased to $1.846 million as of April 30, 2026, from $542,000 as of April 30, 2025.
• The company recorded a gain of $390,000 from the sale of its Exotropin interests.

Negatives

• The company incurred a net loss of $145,000 for the three months ended April 30, 2026, and $997,000 for the six months ended April 30, 2026.
• General and administrative expenses increased by 12.3% to $2.567 million for the three months ended April 30, 2026, compared to the prior year period.
• General and administrative expenses increased by 3.9% to $4.610 million for the six months ended April 30, 2026, compared to the prior year period.
• The company has substantial doubt about its ability to continue as a going concern.
• The company has an accumulated deficit of $68,731,000 as of April 30, 2026.
• Disclosure controls and procedures were not effective as of April 30, 2026.

Risks

• The company has substantial doubt about its ability to continue as a going concern for the 12 months following the issuance of these financial statements.
• The company's ability to process, sell, and distribute products may be restricted by FDA regulations.
• The company has not obtained any opinion or ruling regarding its operations and whether its products are subject to FDA enforcement policies regarding HCT/Ps.
• The company's ability to succeed in its efforts is subject to having sufficient working capital to fund clinical trials and obtaining FDA approval.
• The company's current market capitalization, common stock liquidity, and available authorized shares may hinder its ability to raise equity proceeds.
• Future sources of funding, if any, are anticipated to be costly and dilutive, if available at all.
• If revenues do not increase and stabilize, or if the company's ability to process, sell, and/or distribute products is restricted, or if additional funds cannot be raised, the company might be required to seek alternatives such as asset sales, closure of operations, or bankruptcy protection.
• The company is involved in ongoing legal proceedings, including a complaint filed by Neurovive Holding Co., LLC, Paragon Medical Group, LLC, and Dr. David Buechner, and an action commenced against BioXtek.

Future Outlook

The company anticipates significant revenue growth due to new state legislation enabling the use and sale of stem cell therapies, which is expected to increase demand for its products. Management also expects to leverage real-world data from providers to lower risks associated with future FDA submissions. However, the company remains dependent on additional investment capital to fund ongoing operations and research and development.

Management Comments

• Management cautions all readers that the forward-looking statements contained in this Report are not guarantees of future performance, and management cannot assure any reader that such statements will be realized or the forward-looking events and circumstances will in fact occur.
• The Company expects that SB 1768 and other approved legislation that is expected in other states, will create substantial new demand for current and future stem cell therapy products.
• By enabling physicians to adopt Zeos products for approved indications in Florida, the Company anticipates significant revenue growth and faster advancement of its clinical trial objectives at reduced cost.
• Management anticipates that the Company will remain dependent, for the near future, on additional investment capital to fund ongoing operating expenses and research and development costs related to development of new products and to perform required clinical studies in connection with the sale of its products.
• As of April 30, 2026, based on the factors described above, the Company concluded that there was substantial doubt about its ability to continue to operate as a going concern for the 12 months following the issuance of these financial statements.

Industry Context

StockSavvy.ai notes that Zeo ScientifiX's focus on regenerative medicine and stem cell therapies aligns with growing industry trends, particularly with the emergence of state-level legislation like Florida's SB 1768 that creates new pathways for commercialization. The company's strategy to leverage this legislation for revenue growth and clinical trial data collection is a key differentiator in a rapidly evolving sector.

Comparison to Industry Standards

• The company's revenue growth of 124.6% for the quarter and 79.9% for the six-month period significantly outpaces the typical growth rates seen in many established biopharmaceutical companies, which often experience more moderate, single-digit or low double-digit growth.
• The gross profit margin of approximately 80% is strong and competitive within the specialized biologics and regenerative medicine sector, where high-value, low-volume products can command premium pricing.
• The company's net loss, while improving, is a common characteristic of clinical-stage biopharmaceutical companies investing heavily in research and development. However, the magnitude of the accumulated deficit ($68.7 million) highlights the significant capital required to reach commercialization and profitability, a challenge faced by many in the industry.
• The substantial doubt about the company's ability to continue as a going concern is a critical concern, even with positive revenue trends. This reflects the high-risk, high-reward nature of the biotech industry, where funding is paramount for survival and growth.

Corporate Governance

Legal Proceedings

• Neurovive Holding Co., LLC, Paragon Medical Group, LLC, and Dr. David Buechner filed a complaint asserting claims for breach of contract, breach of fiduciary duty, misappropriation of trade secrets, fraud, promissory estoppel, unjust enrichment, and conversion.
• Dr. Howard Golub filed a complaint alleging a breach of contract for failure to pay severance.
• Exotropin filed a complaint for declaratory judgment concerning a Sales Representative Agreement, which was settled and dismissed with prejudice.
• BioXtek sought to terminate a Binding MOU and Joint Venture; the Company commenced an action against BioXtek for breach of contract, fraudulent inducement, and other claims. Mediation is scheduled.

Related Party Transactions

• For the three months and six months ended April 30, 2026, the Company sold approximately $30,000 of product to a management services organization (MSO) in which Dr. George Shapiro, the Chief Medical Officer and a board member, has an indirect economic interest.
• On May 12, 2026, Greyt Ventures LLC, Dr. George Shapiro, Ian Bothwell, and the Company formed Serephon LLC, a Delaware limited liability company. The Company will supply biologic products to Serephon in exchange for a 50% membership interest.

Stakeholder Impact

• Shareholders: The company's ability to continue as a going concern and potential dilution from future capital raises are significant concerns. However, the strong revenue growth may be viewed positively.
• Employees: The company's financial instability could create job security concerns, although increased operational activity suggests potential for growth.
• Creditors: The company's ability to meet its obligations is under scrutiny due to its going concern status, though current liabilities are manageable relative to assets.
• Customers: The company's focus on new state legislation and product development suggests continued availability of its regenerative medicine products.

Next Steps

• Continue pursuing clinical research and commercial sales strategies compliant with new state stem cell legislation.
• Advance research programs, including clinical studies, product development, and quality/compliance initiatives.
• Enroll patients in the Open-Label Prospective Longitudinal Clinical Trial for PPX.
• Explore further development of additional products for topical aesthetic applications.
• Continue to mitigate potential risks associated with FDA rulings by expanding sales internationally and developing new product offerings.
• Continue to defend against any adverse interpretations by the FDA and/or the state of Florida regarding product classification.
• Await a ruling from the Court on the Motion to Transfer Venue in the Neurovive litigation.
• Participate in mediation for the BioXtek matter.

Key Dates

Recommendation

The company shows promising revenue growth and a narrowing net loss, driven by favorable regulatory changes. However, the persistent substantial doubt about its ability to continue as a going concern, coupled with ongoing legal proceedings and the need for future capital raises, introduces significant risk. A 'hold' recommendation reflects the balance between positive operational momentum and critical financial and operational uncertainties.

Keywords

Zeo ScientifiX, 10-Q, Quarterly Report, Biopharmaceutical, Regenerative Medicine, Stem Cell Therapy, Exosomes, Zofin, PPX, Revenue Growth, Net Loss, Going Concern